Cochrane · systematic review · CD001446
Corticosteroids for Guillain‐Barré syndrome
Hughes, RAC, Brassington, R, Gunn, AA, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 14.3%Low 0 · 0%Moderate 4 · 57.1%High 2 · 28.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 3 versionsCorticosteroid versus control for Guillain‐Barré syndrome
Population: people with Guillain‐Barré syndrome
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Disability grade change after 4 weeks GBS disability grade. Scale from: 0 to 6 Corticosteroid vs control | no estimate extracted | 6 studies · 587 participants | Moderate Downgraded: imprecision, inconsistency |
Disability grade change after 4 weeks ‐ oral regimens GBS disability grade. Scale from: 0 to 6 Corticosteroid vs control | no estimate extracted | 4 studies · 120 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Disability grade change after 4 weeks ‐ intravenous regimens GBS disability grade. Scale from: 0 to 6 Corticosteroid vs control | no estimate extracted | 2 studies · 467 participants | Moderate Downgraded: risk of bias |
Improvement by ≥ 1 grades after 4 weeks GBS disability grade scale Corticosteroid vs control | RR 1.08 [0.93, 1.24] | 5 studies · 567 participants | Moderate Downgraded: risk of bias |
Death or disability after 1 year Corticosteroid vs control | RR 1.51 [0.91, 2.5] | 3 studies · 491 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Adverse events ‐ diabetes mellitus requiring insulin Corticosteroid vs control | RR 2.21 [1.19, 4.12] | 2 studies · 467 participants | High |
Adverse events ‐ hypertension Corticosteroid vs control | RR 0.15 [0.05, 0.41] | 2 studies · 467 participants | High |